Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.

Journal of drugs in dermatology: JDD, 2013 - europepmc.org
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …
被引用次数：102 相关文章

[引用][C] Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open‐label study

AB Gottlieb - J Drugs Dermatol, 2013 - cir.nii.ac.jp
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a
phase II open‐label study | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

AB Gottlieb, RT Matheson, A Menter… - Journal of drugs in …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …